Premier Graphene, Inc. BIEI

BIEI Company Overview

Premier Biomedical, Inc. (OTC: BIEI) is a biotechnology and medical research company focused on the development and commercialization of therapies and treatment platforms targeting chronic diseases, pain management, autoimmune disorders, and infectious diseases. The company has historically positioned itself around intellectual property acquisition, biomedical research collaborations, and the licensing of therapeutic technologies rather than large-scale commercial pharmaceutical manufacturing. Public disclosures indicate that the company has explored applications involving antibody-based therapies, cannabinoid-related formulations, and immune-system-focused treatment approaches.

The company evolved through a series of strategic restructurings and acquisitions of biomedical intellectual property assets, with its business model centered on advancing proprietary therapeutic concepts toward licensing, development partnerships, or commercialization opportunities. Based on publicly available filings and OTC market disclosures, the company has remained in an early-stage development and commercialization phase for much of its operating history. Data regarding sustained revenue generation, large-scale commercial product deployment, or broad market penetration remains limited in available public sources.